Jian Qiao, M.D., Ph.D.

Dr. Jian Qiao received her M.D. from China Medical University in medicine,  and her Ph.D. from Chinese Academy of Science in Tumor Immunology. Before joining UT Southwestern Medical Center, Dr. Qiao has been working on the development of strategies for tumor-targeted delivery of therapeutics including cytokines, cancer cell cytotoxic genes, and oncolytic viruses.  Currently, Dr. Qiao's efforts focus on the development of novel tumor-targeted bispecific antibodies and cytokines to improve the therapeutic index by reducing systemic toxicity while enhancing antitumor immune responses.

Medical School

(2015), Medicine

• Antibody- and Cytokine- based immunotherapies
• Cancer and Autoimmune diseases
• Tumor Microenvironment
• Tumor-targeted delivery of immune therapeutics

Featured Publications

Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity

Moore C, Bae J, Liu L, Li H, Fu YX, Qiao J, JCI Insight 2022 Sep

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.

Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J*, Fu YX*, Nat Biomed Eng. 2021 Nov

Cytokines that target immune killer cells against tumors.

Qiao J*, Fu YX, Cell Mol Immunol. 2020 Jul

Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling.

Han C, Liu Z, Zhang Y, Shen A, Dong C, Zhang A, Moore C, Ren Z, Lu C, Cao X, Zhang CL, Qiao J* Fu YX*, Nat Immunol. 2020 May

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8(+) T Cell Apoptosis.

Qiao J*, Liu Z, Dong C, Luan Y, Zhang A, Moore C, Fu K, Peng J, Wang Y, Ren Z, Han C, Xu T, Fu YX*, Cancer Cell 2019 Jun

DNA sensing and immune responses in cancer therapy.

Qiao J, Tang H, Fu YX, Curr Opin Immunol. 2017 Apr

Adapting conventional cancer treatment for immunotherapy

Qiao J, Liu Z, Fu YX, J Mol Med. 2016 May

Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.

Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, Nettlebeck DM, Han Y, Zhang L, Lesniak MS. Oncoimmunology 2015 Apr

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.

Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bo-no J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K Clin Cancer Res 2008 Jan

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.

Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A, Vile RG, Nat Med. 2008 Jan

• American Association for Cancer Research
• The American Association of Immunologist
• The Society for Immunotherapy of Cancer